{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:08:50Z","timestamp":1788394130679,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"Ethnopharmacological relevance<\/jats:title>Community-acquired pneumonia (CAP) is an acute inflammation of the alveoli and distal bronchi caused by bacterial, viral, or other pathogenic microbial infections. Yinhua Pinggan (YHPG) granules have demonstrated anti-inflammatory, antibacterial, and antiviral effects, suggesting their potential as a treatment option for CAP.<\/jats:p><\/jats:sec>Aim<\/jats:title>To assess the efficacy and safety of traditional Chinese medicine (TCM), YHPG granules, in combination with conventional pneumonia treatments.<\/jats:p><\/jats:sec>Materials and methods<\/jats:title>This randomized, double-blind, placebo-controlled clinical trial was conducted at a medical center in Hangzhou and involved 240 eligible participants. In addition to conventional pneumonia treatment, participants were randomly assigned in a 1:1 ratio to receive either YHPG granules or placebo for 10\u00a0days. The primary outcome measure was the difference in pneumonia cure rates at the end of treatment. Secondary outcomes included chest CT absorption rate, criticality score (SMART-COP score), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, C-reactive protein (CRP) level, lactate (LC) level, procalcitonin (PCT) level, time for symptom recovery, length of hospital stay, and TCM syndrome scores.<\/jats:p><\/jats:sec>Results<\/jats:title>In total, 229 participants were included in the analysis. The pneumonia cure rate in the YHPG granule group was higher than that in the placebo group (37.2% vs. 22.4%, mean difference: 14.75%, 95% CI: 3.05\u201326.46, p<\/jats:italic> &lt; 0.05), indicating the superiority of YHPG granules. The granules significantly improved the chest CT absorption rate, pneumonia severity, and CRP and LC levels (p<\/jats:italic> &lt; 0.05). Additionally, YHPG granules resulted in a shorter recovery time from fever and lung rales, reduced hospital stay, and lowered the TCM syndrome scores than the placebo (p<\/jats:italic> &lt; 0.05). No significant differences were observed in other outcomes between the two groups (p<\/jats:italic> &gt; 0.05). Notably, the use of YHPG granules was associated with fewer adverse reactions.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>YHPG granules are a promising adjunct therapeutic agent for CAP.<\/jats:p><\/jats:sec>Clinical Trial Registration<\/jats:title>https:\/\/www.chictr.org.cn\/showproj.html?proj=127908<\/jats:ext-link>, identifier ChiCTR2100047501.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1446319","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:54:46Z","timestamp":1741082086000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Yinhua Pinggan granules in community-acquired pneumonia: a randomized, double-blind clinical trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiao-Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Ran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/thx.2005.051326","article-title":"A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia","volume":"61","author":"Buising","year":"2006","journal-title":"Thorax"},{"key":"B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1183\/09031936.06.00062505","article-title":"Validation of a predictive rule for the management of community-acquired pneumonia","volume":"27","author":"Capelastegui","year":"2006","journal-title":"Eur. Respir. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/589754","article-title":"SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia","volume":"47","author":"Charles","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/thoraxjnl-2014-206461","article-title":"Lactate on emergency department arrival as a predictor of mortality and site-of-care in pneumonia patients: a cohort study","volume":"70","author":"Chen","year":"2015","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3760\/cma.j.issn.1001-0939.2016.04.005","article-title":"Diagnosis and treatment guidelines for Chinese adult community-acquired pneumonia (2016 edition)","volume":"39","year":"2016","journal-title":"Chin. J. Tuberc. Res. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thx.2010.143982","article-title":"Microbial aetiology of community-acquired pneumonia and its relation to severity","volume":"66","author":"Cill\u00f3niz","year":"2011","journal-title":"Thorax"},{"key":"B7","doi-asserted-by":"publisher","first-page":"c2096","DOI":"10.1136\/bmj.c2096","article-title":"Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis","volume":"340","author":"Costelloe","year":"2010","journal-title":"Bmj"},{"key":"B8","volume-title":"Guiding principles for clinical research of new traditional Chinese medicine drugs trial","year":"2002"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13040-020-00229-4","article-title":"Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of Corona virus disease 2019 (COVID-19) based on network pharmacology","volume":"13","author":"Gao","year":"2020","journal-title":"BioData Min."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"B11","first-page":"5972","article-title":"Safety and effectiveness clinical research of randomized double blinded and positive drug of parallel control and multicenter on clearing away lung heat and dispersing lung qi formula to treat lung qi stagnation syndrome due to exogenous pathogenic heat","volume":"34","author":"He","year":"2019","journal-title":"China J. Tradit. Chin. Med. Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3947\/ic.2018.50.4.287","article-title":"Disease burden and etiologic distribution of community-acquired pneumonia in adults: evolving epidemiology in the era of pneumococcal conjugate vaccines","volume":"50","author":"Heo","year":"2018","journal-title":"Infect. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1602447","DOI":"10.1155\/2022\/1602447","article-title":"Investigation of pharmacological mechanisms of Yinhua pinggan granule on the treatment of pneumonia through network pharmacology and in vitro","volume":"2022","author":"Jin","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jep.2015.03.012","article-title":"Protective and immunomodulatory effect of flos Lonicerae japonicae by augmenting IL-10 expression in a murine model of acute lung inflammation","volume":"168","author":"Kao","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/03639040701378019","article-title":"Characterization of antioxidant activity of extracts from Flos Lonicerae","volume":"33","author":"Lan","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12013-014-0227-7","article-title":"Effects of traditional Chinese medicine Fu Zheng decoction on the immunological function and clinical prognosis of the elderly patients with pneumonia","volume":"71","author":"Li","year":"2015","journal-title":"Cell biochem. Biophys."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.18632\/aging.202622","article-title":"Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19)","volume":"13","author":"Li","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/jhm.414","article-title":"Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia","volume":"4","author":"Lin","year":"2009","journal-title":"J. Hosp. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12866-020-01995-1","article-title":"Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jinf.2010.06.005","article-title":"C-reactive protein: a tool in the follow-up of nosocomial pneumonia","volume":"61","author":"Moreno","year":"2010","journal-title":"J. Infect."},{"key":"B22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jep.2013.10.013","article-title":"Effects of inhalable microparticle of flower of Lonicera japonica in a mouse model of COPD","volume":"151","author":"Park","year":"2014","journal-title":"J. Ethnopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.4268\/cjcmm20151926","article-title":"Effect of Yinghua Pinggan granule against influenza A\/H1N1 virus in vivo. China J","volume":"40","author":"Peng","year":"2015","journal-title":"Chin. Mater. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2016.08.026","article-title":"C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection","volume":"37","author":"Ticinesi","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ijantimicag.2019.02.015","article-title":"Antibacterial and antifungal properties of resveratrol","volume":"53","author":"Vestergaard","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3969\/j.issn.1008-9691.2016.02.005","article-title":"An experimental study on antibacterial effects of Yinhua Pinggan granule","volume":"23","author":"Wan","year":"2016","journal-title":"Chin. J. Integr. Tradit. West. Med. Intensive Crit. Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.19945\/j.cnki.issn.1006-3250.2017.10.016","article-title":"Discussion on clearing away lung heat and dispersing lung qi to treat lung qi stagnation syndrome due to exogenous pathogenic heat","volume":"23","author":"Wan","year":"2017","journal-title":"J. Basic Chin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.13935\/j.cnki.sjzx.171037","article-title":"Diagnostic and therapeutic evaluation criteria on exogenous febrile diseases with evil stagnating lung syndrome(Trial)","volume":"12","author":"Wan","year":"2017","journal-title":"World J. Integr. Tradit. Chin. West. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jep.2011.01.005","article-title":"Mechanism of action of the suppression of influenza virus replication by Ko-Ken Tang through inhibition of the phosphatidylinositol 3-kinase\/Akt signaling pathway and viral RNP nuclear export","volume":"134","author":"Wu","year":"2011","journal-title":"J. Ethnopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ctim.2017.11.012","article-title":"Evaluation on clinical efficacy of Fuzheng Jiedu Huayu Decoction combined with antibiotics in the treatment of pneumonia in the elderly - a multi-center, double-blind, parallel, randomized controlled trial","volume":"37","author":"Xu","year":"2018","journal-title":"Complement. Ther. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1211\/jpp.60.6.0014","article-title":"Anti-angiogenic, antinociceptive and anti-inflammatory activities of Lonicera japonica extract","volume":"60","author":"Yoo","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1093\/infdis\/jiu806","article-title":"Streptococcus pneumoniae-induced oxidative stress in lung epithelial cells depends on pneumococcal autolysis and is reversible by resveratrol","volume":"211","author":"Zahlten","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"151576","DOI":"10.1016\/j.ijmm.2023.151576","article-title":"Anti-inflammatory effect of chlorogenic acid in Klebsiella pneumoniae-induced pneumonia by inactivating the p38MAPK pathway","volume":"313","author":"Zhang","year":"2023","journal-title":"Int. J. Med. Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"948831","DOI":"10.3389\/fphar.2022.948831","article-title":"Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/ptr.5083","article-title":"Puerarin: a review of pharmacological effects","volume":"28","author":"Zhou","year":"2014","journal-title":"Phytother. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1446319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:54:51Z","timestamp":1741082091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1446319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1446319"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1446319","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1446319"}}